Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy (Q38071010)

28 August 2017

1 reference

title

Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy (English)

1 reference

28 August 2017

0 references

Chiara Guglielmi

1

0 references

Andrea Palermo

object named as

Andrea Palermo

series ordinal

2

0 references

Paolo Pozzilli

object named as

Paolo Pozzilli

series ordinal

3

0 references

publication date

1 December 2012

1 reference

Diabetes - Metabolism: Research and Reviews

28 August 2017

published in

1 reference

28 August 2017

volume

28 Suppl 2

1 reference

28 August 2017

page(s)

40-46

1 reference

Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity

28 August 2017

cites work

1 reference

Latent autoimmune diabetes in adults (LADA) should be less latent

21 January 2018

1 reference

Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention

21 January 2018

1 reference

Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow

21 January 2018

1 reference

Latent autoimmune diabetes in adults: A distinct but heterogeneous clinical entity

21 January 2018

1 reference

High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes.

21 January 2018

1 reference

21 January 2018

1 reference

Influence of family history of diabetes on incidence and prevalence of latent autoimmune diabetes of the adult: results from the Nord-Trøndelag Health Study

21 January 2018

1 reference

Latent autoimmune diabetes in adults (LADA)

21 January 2018

1 reference

Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies.

21 January 2018

1 reference

21 January 2018

1 reference

Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe

21 January 2018

1 reference

Metabolic syndrome in adult-onset latent autoimmune diabetes.

21 January 2018

1 reference

Prevalence and correlates of latent autoimmune diabetes in adults in Tianjin, China: a population-based cross-sectional study

21 January 2018

1 reference

GAD65 autoantibody responses in Japanese latent autoimmune diabetes in adult patients

21 January 2018

1 reference

Clinical and genetic characteristics of diabetic patients with high-titer (>10,000 U/ml) of antibodies to glutamic acid decarboxylase.

21 January 2018

1 reference

The prevalence and characteristics of latent autoimmune diabetes in adults (LADA) and its relation with chronic complications in a clinical department of a university hospital in Korea.

21 January 2018

1 reference

Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70).

21 January 2018

1 reference

Mechanisms of sulfonylurea-induced insulin release

21 January 2018

1 reference

Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus

21 January 2018

1 reference

Effect of prophylactic insulin treatment on the number of ER-MP23+ macrophages in the pancreas of NOD mice. Is the prevention of diabetes based on beta-cell rest?

21 January 2018

1 reference

Exposure to exogenous insulin promotes IgG1 and the T-helper 2-associated IgG4 responses to insulin but not to other islet autoantigens.

21 January 2018

1 reference

Insulin treatment in patients with type 1 diabetes induces upregulation of regulatory T-cell markers in peripheral blood mononuclear cells stimulated with insulin in vitro

21 January 2018

1 reference

Isohormonal therapy of endocrine autoimmunity.

21 January 2018

1 reference

Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals

21 January 2018

1 reference

Pioglitazone and sulfonylureas: effectively treating type 2 diabetes

21 January 2018

1 reference

Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes

21 January 2018

1 reference

Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death

21 January 2018

1 reference

Rosiglitazone prevents diabetes by increasing beta-cell mass in an animal model of type 2 diabetes characterized by reduced beta-cell mass at birth

21 January 2018

1 reference

Gene expression regulated by pioglitazone and exenatide in normal and diabetic rat islets exposed to lipotoxicity

21 January 2018

1 reference

Beta-cell protection and therapy for latent autoimmune diabetes in adults

21 January 2018

1 reference

Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA).

21 January 2018

1 reference

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

Exendin-4 stimulation of cyclin A2 in beta-cell proliferation

21 January 2018

1 reference

beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1.

21 January 2018

1 reference

Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.

21 January 2018

1 reference

Low-risk HLA genotype in Type 1 diabetes is associated with less destruction of pancreatic B-cells 12 months after diagnosis.

21 January 2018

1 reference

NOD mouse diabetes: the ubiquitous mouse hsp60 is a beta-cell target antigen of autoimmune T cells

21 January 2018

1 reference

Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

21 January 2018

1 reference

Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial

21 January 2018

1 reference

Immunomodulation for the prevention of SPIDDM and LADA.

21 January 2018

1 reference

Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes

21 January 2018

1 reference

GAD treatment and insulin secretion in recent-onset type 1 diabetes

21 January 2018

1 reference

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial

21 January 2018

1 reference

Identifying latent autoimmune diabetes in adults in Korea: the role of C-peptide and metabolic syndrome

21 January 2018

1 reference

UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes

21 January 2018

1 reference

Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop

21 January 2018

1 reference

7 January 2021

Diagnosis and classification of diabetes mellitus

1 reference

7 January 2021

Immunogenetic and clinical characterization of slowly progressive IDDM

1 reference

7 January 2021

Age, overweight and physical inactivity increase the risk of latent autoimmune diabetes in adults: results from the Nord-Trøndelag health study

1 reference

7 January 2021

Latent autoimmune diabetes in adults: a guide for the perplexed

1 reference

7 January 2021

A clinical screening tool identifies autoimmune diabetes in adults

1 reference

7 January 2021

Latent autoimmune diabetes in adults in a South Asian population of the U.K.

1 reference

7 January 2021

Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group

1 reference

7 January 2021

Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus

1 reference

7 January 2021

Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.2345

1 reference

28 August 2017

1 reference